Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 2/20 | 0.58 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.58 |
| ▸ | PAK1 | Q13153 | 8/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.49 |
| ▸ | PI4KA | P42356 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.49 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.49 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.49 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29894717 | 1.00 | AKT2 (0.70) | AKT2LMNAMAPTHTTJAK3 | |
| Hydrochloric Acid SCHEMBL2799346 | 0.84 | AKT2 (0.67) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL4996432 | 0.84 | LMNA (0.68) | AKT2LMNAMAPTHTTJAK3 | |
| Hydrochloric Acid SCHEMBL28363987 | 0.84 | AKT2 (0.67) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL1003794 | 0.83 | AKT2 (1.00) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL31677414 | 0.83 | AKT2 (1.00) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL4128044 | 0.80 | AKT2 (1.00) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL5278122 | 0.80 | LMNA (0.67) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL1792018 | 0.80 | MAPT (1.00) | AKT2LMNAMAPTHTTRPS6KB1 | |
| SCHEMBL27644898 | 0.78 | LMNA (0.60) | AKT2LMNAMAPTHTTRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-03-02 | — | — | US | disclosed |
| WO-2021123798-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2021-06-24 | — | — | WO | disclosed |
| EP-2188291-B1 | FUSED BICYCLIC PYRIMIDINES | Bayer Pharma AG (DE) | 2012-09-19 | — | — | EP | disclosed |
| US-7994172-B2 | [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism | EXELIXIS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| EP-2125805-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | Astex Therapeutics Limited (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | EXELIXIS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008075109-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230064189-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PLATINUM-RESISTANT CANCER | DPYD, ABCC1, TYMP | AKT2 2208/4885LMNA 4582/4885MAPT 4343/4885 |
| US-20080188482-A1 | [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases | PDPK1, MTOR, RPS6KA2 | AKT2 6/4885LMNA 4117/4885MAPT 3426/4885 |
| US-20100093748-A1 | SUBSTITUTED PIPERIDINES HAVING PROTEIN KINASE INHIBITING ACTIVITY | PRKAR2B, GRK3, PRKAR2A | AKT2 35/4885LMNA 1923/4885MAPT 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.